Roquefort Therapeutics plc
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more
Roquefort Therapeutics plc (ROQAF) - Total Liabilities
Latest total liabilities as of June 2025: $909.12K USD
Based on the latest financial reports, Roquefort Therapeutics plc (ROQAF) has total liabilities worth $909.12K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Roquefort Therapeutics plc - Total Liabilities Trend (2021–2024)
This chart illustrates how Roquefort Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Roquefort Therapeutics plc Competitors by Total Liabilities
The table below lists competitors of Roquefort Therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oragenics Inc
NYSE MKT:OGEN
|
USA | $2.87 Million |
|
Tirta Mahakam Resources Tbk
JK:TIRT
|
Indonesia | Rp1.07 Trillion |
|
Equippp Social Impact Technologies Limited
NSE:EQUIPPP
|
India | ₹168.61 Million |
|
Manufatura de Brinquedos Estrela SA
SA:ESTR3
|
Brazil | R$588.43 Million |
|
Bank Leumi Le-Israel B.M
TA:LUMI
|
Israel | ILA804.84 Billion |
|
ECS Botanics Holdings Ltd
AU:ECS
|
Australia | AU$11.02 Million |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
Malaysia | RM25.58 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Roquefort Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roquefort Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roquefort Therapeutics plc (2021–2024)
The table below shows the annual total liabilities of Roquefort Therapeutics plc from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $861.73K | +46.30% |
| 2023-12-31 | $589.02K | +4.89% |
| 2022-12-31 | $561.58K | +17.63% |
| 2021-12-31 | $477.43K | -- |